Femasys advances FDA review path for FemBloc
Femasys (NASDAQ:FEMY) announced that the U.S. FDA approved its modular premarket approval submission approach for FemBloc, the company’s investigational non-surgical permanent birth control technology.

TV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
Femasys (NASDAQ:FEMY) announced that the U.S. FDA approved its modular premarket approval submission approach for FemBloc, the company’s investigational non-surgical permanent birth control technology.
Intelligent Bio Solutions (NASDAQ:INBS) reported fiscal 2026 revenue of $4.2 million, up 38% year over year, driven by growth in its installed reader base and consumable cartridge sales.
Viking Holdings (NYSE:VIK) reported second-quarter 2026 revenue of $2.19 billion, up 16.5% year over year, with adjusted EBITDA increasing 18.2% to $748.4 million.
Lowe’s (NYSE:LOW) reported second-quarter 2026 sales of $26 billion, up from $24 billion, while net earnings held at $2.4 billion.
US national debt is approaching $40 trillion, increasing focus on the country’s borrowing and fiscal outlook.
Flex LNG (NYSE:FLNG) reported Q2 2026 vessel operating revenue of $106.8 million, up from $80.5 million in Q1, as fleet-wide TCE rates increased to $86,119 per day.
Goldman Sachs agreed to buy LCN Capital Partners for up to $410 million.
Bitcoin (CRYPTO:BTC) worth about $13.7 million moved from a wallet that had been inactive since 2012.
Opera (NASDAQ:OPRA) reported second-quarter 2026 revenue of $178.1 million, up 25% year over year, with adjusted EBITDA increasing 32% to $42.4 million.
Evolution Mining (ASX:EVN) reported a $1.56 billion underlying net profit and increased its final dividend to 21 cents per share.